Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis.

Ortiz-Montero P, Liu-Bordes WY, Londoño-Vallejo A, Vernot JP.

Cancer Manag Res. 2018 Nov 16;10:5767-5784. doi: 10.2147/CMAR.S176654. eCollection 2018.

2.

Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.

Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lépine C, Venisse A, Robidel E, Verkarre V, Meatchi T, Sibony M, Amar L, Bertherat J, de Reyniès A, Londoño-Vallejo A, Favier J, Castro-Vega LJ, Gimenez-Roqueplo AP.

Clin Cancer Res. 2018 Oct 9. doi: 10.1158/1078-0432.CCR-18-0139. [Epub ahead of print]

PMID:
30301828
3.

Genome-wide Control of Heterochromatin Replication by the Telomere Capping Protein TRF2.

Mendez-Bermudez A, Lototska L, Bauwens S, Giraud-Panis MJ, Croce O, Jamet K, Irizar A, Mowinckel M, Koundrioukoff S, Nottet N, Almouzni G, Teulade-Fichou MP, Schertzer M, Perderiset M, Londoño-Vallejo A, Debatisse M, Gilson E, Ye J.

Mol Cell. 2018 May 3;70(3):449-461.e5. doi: 10.1016/j.molcel.2018.03.036.

PMID:
29727617
4.

Human RTEL1 stabilizes long G-overhangs allowing telomerase-dependent over-extension.

Porreca RM, Glousker G, Awad A, Matilla Fernandez MI, Gibaud A, Naucke C, Cohen SB, Bryan TM, Tzfati Y, Draskovic I, Londoño-Vallejo A.

Nucleic Acids Res. 2018 May 18;46(9):4533-4545. doi: 10.1093/nar/gky173.

5.
6.

Telomere Strand-Specific Length Analysis by Fluorescent In Situ Hybridization (Q-CO-FISH).

Ourliac-Garnier I, Londoño-Vallejo A.

Methods Mol Biol. 2017;1587:41-54. doi: 10.1007/978-1-4939-6892-3_4.

PMID:
28324496
7.

Telomere Length Analysis by Quantitative Fluorescent in Situ Hybridization (Q-FISH).

Ourliac-Garnier I, Londoño-Vallejo A.

Methods Mol Biol. 2017;1587:29-39. doi: 10.1007/978-1-4939-6892-3_3.

PMID:
28324495
8.

Chromatin immunoprecipitation in microfluidic droplets: towards fast and cheap analyses.

Teste B, Champ J, Londono-Vallejo A, Descroix S, Malaquin L, Viovy JL, Draskovic I, Mottet G.

Lab Chip. 2017 Jan 31;17(3):530-537. doi: 10.1039/c6lc01535b.

PMID:
28092380
9.

Extended clinical and genetic spectrum associated with biallelic RTEL1 mutations.

Touzot F, Kermasson L, Jullien L, Moshous D, Ménard C, Ikincioğullari A, Doğu F, Sari S, Giacobbi-Milet V, Etzioni A, Soulier J, Londono-Vallejo A, Fischer A, Callebaut I, de Villartay JP, Leblanc T, Kannengiesser C, Revy P.

Blood Adv. 2016 Nov 22;1(1):36-46. doi: 10.1182/bloodadvances.2016001313. eCollection 2016 Nov 29.

10.

A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion.

Verlingue L, Dugourd A, Stoll G, Barillot E, Calzone L, Londoño-Vallejo A.

Aging Cell. 2016 Dec;15(6):1018-1026. doi: 10.1111/acel.12504. Epub 2016 Sep 9.

11.

Mutations of the RTEL1 Helicase in a Hoyeraal-Hreidarsson Syndrome Patient Highlight the Importance of the ARCH Domain.

Jullien L, Kannengiesser C, Kermasson L, Cormier-Daire V, Leblanc T, Soulier J, Londono-Vallejo A, de Villartay JP, Callebaut I, Revy P.

Hum Mutat. 2016 May;37(5):469-72. doi: 10.1002/humu.22966. Epub 2016 Feb 23.

PMID:
26847928
12.

TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End Protection.

Benarroch-Popivker D, Pisano S, Mendez-Bermudez A, Lototska L, Kaur P, Bauwens S, Djerbi N, Latrick CM, Fraisier V, Pei B, Gay A, Jaune E, Foucher K, Cherfils-Vicini J, Aeby E, Miron S, Londoño-Vallejo A, Ye J, Le Du MH, Wang H, Gilson E, Giraud-Panis MJ.

Mol Cell. 2016 Jan 21;61(2):274-86. doi: 10.1016/j.molcel.2015.12.009. Epub 2016 Jan 7.

13.

Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension.

Izikki M, Hoang E, Draskovic I, Mercier O, Lecerf F, Lamrani L, Liu WY, Guignabert C, Fadel E, Dorfmuller P, Humbert M, Londoño-Vallejo A, Eddahibi S.

J Am Coll Cardiol. 2015 Oct 27;66(17):1942-3. doi: 10.1016/j.jacc.2015.08.869. No abstract available.

14.

The senescent microenvironment promotes the emergence of heterogeneous cancer stem-like cells.

Castro-Vega LJ, Jouravleva K, Ortiz-Montero P, Liu WY, Galeano JL, Romero M, Popova T, Bacchetti S, Vernot JP, Londoño-Vallejo A.

Carcinogenesis. 2015 Oct;36(10):1180-92. doi: 10.1093/carcin/bgv101. Epub 2015 Jul 13.

PMID:
26168819
15.

Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats.

Jacquin S, Rincheval V, Mignotte B, Richard S, Humbert M, Mercier O, Londoño-Vallejo A, Fadel E, Eddahibi S.

PLoS One. 2015 Jun 29;10(6):e0131940. doi: 10.1371/journal.pone.0131940. eCollection 2015.

16.

Telomere regulation during ageing and tumorigenesis of the grey mouse lemur.

Trochet D, Mergui X, Ivkovic I, Porreca RM, Gerbault-Seureau M, Sidibe A, Richard F, Londono-Vallejo A, Perret M, Aujard F, Riou JF.

Biochimie. 2015 Jun;113:100-10. doi: 10.1016/j.biochi.2015.04.002. Epub 2015 Apr 14.

17.

Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y.

Cancer. 2015 May 1;121(9):1422-30. doi: 10.1002/cncr.29233. Epub 2015 Jan 13.

18.

Human regulator of telomere elongation helicase 1 (RTEL1) is required for the nuclear and cytoplasmic trafficking of pre-U2 RNA.

Schertzer M, Jouravleva K, Perderiset M, Dingli F, Loew D, Le Guen T, Bardoni B, de Villartay JP, Revy P, Londoño-Vallejo A.

Nucleic Acids Res. 2015 Feb 18;43(3):1834-47. doi: 10.1093/nar/gku1402. Epub 2015 Jan 27.

19.

CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F.

Oncotarget. 2015 May 20;6(14):11994-2008.

20.

The basic N-terminal domain of TRF2 limits recombination endonuclease action at human telomeres.

Saint-Léger A, Koelblen M, Civitelli L, Bah A, Djerbi N, Giraud-Panis MJ, Londoño-Vallejo A, Ascenzioni F, Gilson E.

Cell Cycle. 2014;13(15):2469-74. doi: 10.4161/cc.29422.

21.

A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging.

Mottet G, Perez-Toralla K, Tulukcuoglu E, Bidard FC, Pierga JY, Draskovic I, Londono-Vallejo A, Descroix S, Malaquin L, Louis Viovy J.

Biomicrofluidics. 2014 Apr 7;8(2):024109. doi: 10.1063/1.4871035. eCollection 2014 Mar.

22.

A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).

Jeitany M, Pineda JR, Liu Q, Porreca RM, Hoffschir F, Desmaze C, Silvestre DC, Mailliet P, Junier MP, Londoño-Vallejo A, Ségal-Bendirdjian E, Chneiweiss H, Boussin FD.

Int J Cancer. 2015 Apr 1;136(7):1546-58. doi: 10.1002/ijc.29171. Epub 2014 Sep 11.

23.

Telomere recombination and the ALT pathway: a therapeutic perspective for cancer.

Draskovic I, Londono-Vallejo A.

Curr Pharm Des. 2014;20(41):6466-71. Review.

PMID:
24975611
24.

Recombinogenic telomeres in diploid Sorex granarius (Soricidae, Eulipotyphla) fibroblast cells.

Zhdanova NS, Draskovic I, Minina JM, Karamysheva TV, Novo CL, Liu WY, Porreca RM, Gibaud A, Zvereva ME, Skvortsov DA, Rubtsov NB, Londoño-Vallejo A.

Mol Cell Biol. 2014 Aug;34(15):2786-99. doi: 10.1128/MCB.01697-13. Epub 2014 May 19.

25.

Alternative Lengthening of Telomeres is characterized by reduced compaction of telomeric chromatin.

Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M, Arnoult N, Londoño-Vallejo A, Decottignies A.

Nucleic Acids Res. 2014 Apr;42(7):4391-405. doi: 10.1093/nar/gku114. Epub 2014 Feb 5.

26.

[RTEL1 (regulator of telomere elongation helicase 1), a DNA helicase essential for genome stability].

Le Guen T, Jullien L, Schertzer M, Lefebvre A, Kermasson L, de Villartay JP, Londoño-Vallejo A, Revy P.

Med Sci (Paris). 2013 Dec;29(12):1138-44. doi: 10.1051/medsci/20132912018. Epub 2013 Dec 20. Review. French.

27.

The C-terminal extension of human RTEL1, mutated in Hoyeraal-Hreidarsson syndrome, contains harmonin-N-like domains.

Faure G, Revy P, Schertzer M, Londono-Vallejo A, Callebaut I.

Proteins. 2014 Jun;82(6):897-903. doi: 10.1002/prot.24438. Epub 2013 Nov 22.

PMID:
24130156
28.

Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome.

Deng Z, Glousker G, Molczan A, Fox AJ, Lamm N, Dheekollu J, Weizman OE, Schertzer M, Wang Z, Vladimirova O, Schug J, Aker M, Londoño-Vallejo A, Kaestner KH, Lieberman PM, Tzfati Y.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3408-16. doi: 10.1073/pnas.1300600110. Epub 2013 Aug 19.

29.

Pulmonary alveolar proteinosis revealing a telomerase disease.

Marchand-Adam S, Diot B, Magro P, De Muret A, Guignabert C, Kannengiesser C, Londono-Vallejo A, Draskovic I, Toutain A, Diot P.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):402-4. doi: 10.1164/rccm.201301-0010LE. No abstract available.

PMID:
23905534
30.

TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E.

Nat Cell Biol. 2013 Jul;15(7):818-28. doi: 10.1038/ncb2774. Epub 2013 Jun 23.

PMID:
23792691
31.

Mutant mice lacking the p53 C-terminal domain model telomere syndromes.

Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais C, Bourdon JC, Huerre M, Londono-Vallejo A, Toledo F.

Cell Rep. 2013 Jun 27;3(6):2046-58. doi: 10.1016/j.celrep.2013.05.028. Epub 2013 Jun 13.

32.

A new role for histone deacetylase 5 in the maintenance of long telomeres.

Novo CL, Polese C, Matheus N, Decottignies A, Londono-Vallejo A, Castronovo V, Mottet D.

FASEB J. 2013 Sep;27(9):3632-42. doi: 10.1096/fj.12-224204. Epub 2013 May 31.

33.

Estrogen-dependent dynamic profile of eNOS-DNA associations in prostate cancer.

Nanni S, Aiello A, Re A, Guffanti A, Benvenuti V, Colussi C, Castro-Vega LJ, Felsani A, Londono-Vallejo A, Capogrossi MC, Bacchetti S, Gaetano C, Pontecorvi A, Farsetti A.

PLoS One. 2013 May 3;8(5):e62522. doi: 10.1371/journal.pone.0062522. Print 2013.

34.

Human RTEL1 deficiency causes Hoyeraal-Hreidarsson syndrome with short telomeres and genome instability.

Le Guen T, Jullien L, Touzot F, Schertzer M, Gaillard L, Perderiset M, Carpentier W, Nitschke P, Picard C, Couillault G, Soulier J, Fischer A, Callebaut I, Jabado N, Londono-Vallejo A, de Villartay JP, Revy P.

Hum Mol Genet. 2013 Aug 15;22(16):3239-49. doi: 10.1093/hmg/ddt178. Epub 2013 Apr 15.

PMID:
23591994
35.

The heterochromatic chromosome caps in great apes impact telomere metabolism.

Novo C, Arnoult N, Bordes WY, Castro-Vega L, Gibaud A, Dutrillaux B, Bacchetti S, Londoño-Vallejo A.

Nucleic Acids Res. 2013 May;41(9):4792-801. doi: 10.1093/nar/gkt169. Epub 2013 Mar 21.

36.

Telomere crisis in kidney epithelial cells promotes the acquisition of a microRNA signature retrieved in aggressive renal cell carcinomas.

Castro-Vega LJ, Jouravleva K, Liu WY, Martinez C, Gestraud P, Hupé P, Servant N, Albaud B, Gentien D, Gad S, Richard S, Bacchetti S, Londoño-Vallejo A.

Carcinogenesis. 2013 May;34(5):1173-80. doi: 10.1093/carcin/bgt029. Epub 2013 Jan 27.

PMID:
23358853
37.

Telomere recombination and alternative telomere lengthening mechanisms.

Draskovic I, Londono Vallejo A.

Front Biosci (Landmark Ed). 2013 Jan 1;18:1-20. Review.

PMID:
23276906
38.

Telomere dynamics in mammals.

Silvestre DC, Londoño-Vallejo A.

Genome Dyn. 2012;7:29-45. doi: 10.1159/000337128. Epub 2012 Jun 25. Review.

PMID:
22759812
39.

Telomere strand-specific length analysis by fluorescent in situ hybridization (Q-CO-FISH).

Ourliac-Garnier I, Londoño-Vallejo A.

Methods Mol Biol. 2011;735:33-46. doi: 10.1007/978-1-61779-092-8_4.

PMID:
21461809
40.

Telomere length analysis by quantitative fluorescent in situ hybridization (Q-FISH).

Ourliac-Garnier I, Londoño-Vallejo A.

Methods Mol Biol. 2011;735:21-31. doi: 10.1007/978-1-61779-092-8_3.

PMID:
21461808
41.

TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage.

Ye J, Lenain C, Bauwens S, Rizzo A, Saint-Léger A, Poulet A, Benarroch D, Magdinier F, Morere J, Amiard S, Verhoeyen E, Britton S, Calsou P, Salles B, Bizard A, Nadal M, Salvati E, Sabatier L, Wu Y, Biroccio A, Londoño-Vallejo A, Giraud-Panis MJ, Gilson E.

Cell. 2010 Jul 23;142(2):230-42. doi: 10.1016/j.cell.2010.05.032.

42.

Replication timing of human telomeres is chromosome arm-specific, influenced by subtelomeric structures and connected to nuclear localization.

Arnoult N, Schluth-Bolard C, Letessier A, Drascovic I, Bouarich-Bourimi R, Campisi J, Kim SH, Boussouar A, Ottaviani A, Magdinier F, Gilson E, Londoño-Vallejo A.

PLoS Genet. 2010 Apr 22;6(4):e1000920. doi: 10.1371/journal.pgen.1000920.

43.

Human POT1 is required for efficient telomere C-rich strand replication in the absence of WRN.

Arnoult N, Saintome C, Ourliac-Garnier I, Riou JF, Londoño-Vallejo A.

Genes Dev. 2009 Dec 15;23(24):2915-24. doi: 10.1101/gad.544009.

44.

Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.

Draskovic I, Arnoult N, Steiner V, Bacchetti S, Lomonte P, Londoño-Vallejo A.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15726-31. doi: 10.1073/pnas.0907689106. Epub 2009 Aug 26.

45.

Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.

Temime-Smaali N, Guittat L, Wenner T, Bayart E, Douarre C, Gomez D, Giraud-Panis MJ, Londono-Vallejo A, Gilson E, Amor-Guéret M, Riou JF.

EMBO J. 2008 May 21;27(10):1513-24. doi: 10.1038/emboj.2008.74. Epub 2008 Apr 17.

46.

[Targeting telomeres to enforce cancer cells to senesce].

Londoño-Vallejo A, Lenain C, Gilson E.

Med Sci (Paris). 2008 Apr;24(4):383-9. doi: 10.1051/medsci/2008244383. Review. French.

47.

Telomerase reverse transcriptase haploinsufficiency and telomere length in individuals with 5p- syndrome.

Du HY, Idol R, Robledo S, Ivanovich J, An P, Londono-Vallejo A, Wilson DB, Mason PJ, Bessler M.

Aging Cell. 2007 Oct;6(5):689-97.

48.

Telomere length profiles in humans: all ends are not equal.

Gilson E, Londoño-Vallejo A.

Cell Cycle. 2007 Oct 15;6(20):2486-94. Epub 2007 Jul 26. Review.

PMID:
17726375
49.

The effect of TERC haploinsufficiency on the inheritance of telomere length.

Goldman F, Bouarich R, Kulkarni S, Freeman S, Du HY, Harrington L, Mason PJ, Londoño-Vallejo A, Bessler M.

Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17119-24. Epub 2005 Nov 11.

50.

Resistance to the short term antiproliferative activity of the G-quadruplex ligand 12459 is associated with telomerase overexpression and telomere capping alteration.

Gomez D, Aouali N, Londoño-Vallejo A, Lacroix L, Mégnin-Chanet F, Lemarteleur T, Douarre C, Shin-ya K, Mailliet P, Trentesaux C, Morjani H, Mergny JL, Riou JF.

J Biol Chem. 2003 Dec 12;278(50):50554-62. Epub 2003 Oct 2.

Supplemental Content

Loading ...
Support Center